GSK3A and neoplasm: The data from both the EL4 (Figure 2) and B16 (Figure 3) flank tumors demonstrate non-redundant activity of the GSK-3α and GSK-3β isoforms, with genetic inactivation of GSK-3β resulting in enhanced rejection of both tumor types in the flank.